Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis

Table 9 Physician characteristics

	Physicians (N = 168)
	N (%) or Mean (SD)	Median	[Range]
Practice characteristics
Main practice setting, N (%)
Academic	69 (41.1 %)
Non-academic	99 (58.9 %)
Practice location, N (%)
Northeast	61 (36.3 %)
South	42 (25.0 %)
Midwest	35 (20.8 %)
West	30 (17.9 %)
Physician characteristics
Years in pulmonology practice, mean (SD) median [min, max]	15.0 (6.4)	14	[3, 30]
Percentage of time spent in inpatient vs. outpatient settings, mean (SD) median [min, max]
Inpatient settings	39.0 (17.2)	40	[5, 90]
Outpatient settings	61.0 (17.2)	60	[10, 95]
Participation in IPF-related research during the past year, N (%)^a,b
IPF clinical trial involvement	20 (11.9 %)
Other IPF research involvement	13 (7.7 %)
None	138 (82.1 %)
Physician-reported profile of treated patients (January 1, 2011 – June 20, 2013)
Number of patients diagnosed with interstitial lung disease (ILD), mean (SD) median [min, max]	132.7 (182.4)	60	[4, 1000]
Number of ILD patients diagnosed with IPF	76.2 (93.5)	45	[3, 600]
Number of deaths within 6 months of IPF diagnosis	10.0 (17.4)	5	[0, 150]
Number of deaths within 12 months of IPF diagnosis	20.6 (38.7)	8	[0, 350]
Percent of ILD patients diagnosed with IPF	68.4 (26.3)	72	[8, 100]
Percent of IPF patients dying within 6 months of IPF diagnosis	12.3 (11.4)	10	[0, 60]
Percent of IPF patients dying within 12 months of IPF diagnosis	26.0 (22.6)	20	[0, 94]
Number of charts abstracted^c, mean (SD) median [min, max]	2.9 (1.2)	3	[1, 4]

^aResearch involvement includes IPF-related basic clinical research, epidemiology studies, outcomes studies, etc.
^bPhysicians were allowed to select multiple values for type of research involvement, so counts and percentages may not sum to the total N or 100 %
^cPhysicians have been permitted to abstract a maximum of 4 patient charts

ISSN: 1471-2466